HURA (TuHURA Biosciences) Short-Term Debt : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences Short-Term Debt?

TuHURA Biosciences's Short-Term Debt for the quarter that ended in Sep. 2024 was $0.00 Mil.

TuHURA Biosciences's annual Short-Term Debt declined from Dec. 2021 ($0.64 Mil) to Dec. 2022 ($0.00 Mil) but then stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

TuHURA Biosciences Short-Term Debt Historical Data

The historical data trend for TuHURA Biosciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Short-Term Debt Chart

TuHURA Biosciences Annual Data

Trend

Dec21

Dec22

Dec23

Short-Term Debt

0.64

TuHURA Biosciences Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial			-	-	-	-	-

TuHURA Biosciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

TuHURA Biosciences Short-Term Debt Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

TuHURA Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612

Website

https://www.tuhurabio.com

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.